In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on LivaNova PLC (NASDAQ: LIVN), with a price target of $140. The company’s shares closed on Friday at $124.79, close to its 52-week high of $131.54.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 18.4% and a 77.3% success rate. Wise covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Obalon Therapeutics Inc, and Boston Scientific Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LivaNova PLC with a $133.40 average price target.
See today’s analyst top recommended stocks >>
Based on LivaNova PLC’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $15.28 million. In comparison, last year the company had a net profit of $47.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments.
